Unfolding Catalytic Routes to APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Unfolding Catalytic Routes to APIs
Chemocatalytic and biocatalytic routes show promise for more efficient syntheses of select active ingredients.


Pharmaceutical Technology



Patricia Van Arnum
Optimizing a synthesis for an active pharmaceutical ingredient (API) or intermediate often requires developing an alternative catalytic route. Recent developments in chemocatalysis and biocatalysis show several interesting approaches.

Metal-catalyzed hydrogen-mediated C–C bond formation

Catalytic hydrogenation is widely used in API synthesis, including asymmetric reactions. Catalytic hydrogenation involves the addition of hydrogen to unsaturated organic molecules to form saturated compounds. Conventional hydrogenation involves hydrogen delivery to a single functional group, but the technique of hydrogen delivery across multiple functional groups with concomitant carbon–carbon (C–C) bond formation has been limited.

Hydrogen-mediated C–C bond formation has been used for alkene hydroformylation and the Fischer–Tropsch reaction, but these reactions require carbon dioxide as a coupling partner (1). Work by Michael J. Krische, professor of chemistry at the University of Texas at Austin, shows that organometallic intermediates arising transiently under the conditions of catalytic hydrogenation may be captured by conventional electrophiles such as carbonyl compounds and imines. This approach avoids using organometallic reagents such as Grignard and Gilman reagents in carbonyl and imine addition reactions. Instead, under hydrogen-mediated C–C bond formation, the catalytic C–C coupling is achieved by exposing two or more molecules to gaseous hydrogen in the presence of a metallic catalyst (1, 2).

Krische's work in hydrogen-mediated C–C bond formation was recognized last year with the Dowpharma Prize Lecture for Creativity in Chiral Chemistry at Chiral USA and the Environmental Protection Agency's Presidential Green Challenge Award.

For pharmaceutical syntheses, hydrogen-mediated C–C bond formation may achieve high optical purity in enantioselective reactions using various chiral ligands in transition-metal catalysts. In a recent example, Krische reported enantioselective reductive aldol couplings of vinyl ketones through a rhodium catalyst modified by a new monodentate Taddol-like phosphonite ligand (3). In another example, Krische reported on hydrogen-mediated C–C bond formations catalyzed by iridium for the direct regioselective reductive coupling of alkyl-substituted alkynes to activated ketones (1, 4).

Enantioselective iridium-catalyzed imine vinylation is another approach using hydrogen-mediated C–C bond formation. In this method, alkyenes are hydrogenated in the presence of N-arylsulfonyl imines using an iridium catalyst modified by (R)-Cl-MeO-BIPHEP to obtain the corresponding allylic amines in high optical purity (5).


Figure 1: Enalapril (1) and lisinopril (2) are active ingredients that could potentially be synthesized using hydrogen-mediated carbon–carbon bond formation. (ALL MOLECULES IN FIGURE ARE COURTESY OF US FOOD AND DRUG ADMINISTRATION)
Hydrogen-mediated C–C bond formation may also allow chemists to use less expensive feedstocks in API synthesis. Two cardiovascular drugs, for example, "Vasotec" (enalapril) by Merck & Co. (Whitehouse Station) and "Zestril" (lisinopril) by AstraZeneca (London) could be synthesized by hydrogen-mediated C–C bond formation using styrene as a starting material (see Figure 1). Ibuprofen and naproxen may also be synthesized by hydrogen-mediated C–C bond formation using carbon dioxide as the starting material (1).

The enantioselective coupling of acetylene, another low-cost feedstock, also shows the promise of hydrogen-mediated C–C bond formation. Krische's work shows that exposing aldehydes or α-ketoesters to equal volumes of acetylene and hydrogen gas in the presence of cationic rhodium catalysts provides products of Z-butadienylation: two molecules of acetylene, a molecule of a vicinal dicarbonyl compound, and one molecule of elemental hydrogren (6).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here